News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biothera Release: Combination of Imprime PGG and Erbitux Doubles the Therapeutic Response in Colorectal Cancer Patients in Phase Ib/IIa Trial


7/6/2010 10:39:15 AM

BARCELONA, Spain--(BUSINESS WIRE)--The combination of Biothera’s experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

Read at BioSpace.com


comments powered by Disqus
Biothera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES